RecallRadar

FDA Drug recall D-0551-2025

Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL vials/carton, Rx Only, Manufactured by: Hikma Berkeley Heights, NJ 07922, NDC# 0641-6044-25

On 2025-08-06 the FDA classified a Class II recall of Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL vials/carton, Rx Only, Manufactured by: Hikma Berkeley Heights, NJ 07922, NDC# 0641-6044-25 by Hikma Pharmaceuticals Usa, citing failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0551-2025
ClassificationClass II
Statusongoing
Initiated2025-07-22
Published2025-08-06
Last updated2026-09-13 11:52 UTC
CompanyHikma Pharmaceuticals Usa
DistributionUS

Product

Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL vials/carton, Rx Only, Manufactured by: Hikma Berkeley Heights, NJ 07922, NDC# 0641-6044-25

Reason

Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds

Identifiers

ndc0641-6044-01
ndc0641-6044-25
ndc0641-6046-01
ndc0641-6046-10
ndc0641-6045-01
ndc0641-6045-25
ndc0641-6047-01
ndc0641-6047-10
code_infoLot # K24118, exp. date 10/31/2026

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0551-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.